• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Spectral AI Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    3/4/25 4:08:32 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care
    Get the next $MDAI alert in real time by email
    false 0001833498 0001833498 2024-12-12 2024-12-12 0001833498 MDAI:CommonStockParValue0.0001PerShareMember 2024-12-12 2024-12-12 0001833498 MDAI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember 2024-12-12 2024-12-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(D) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): December 12, 2024

     

    SPECTRAL AI, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40058   85-3987148
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    2515 McKinney Avenue, Suite 1000

    Dallas, Texas

      75201
    (Address of principal executive offices)   (Zip Code)

     

    (972) 499-4934

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbols   Name of each exchange on
    which registered
    Common Stock, par value $0.0001 per share   MDAI   The Nasdaq Stock Market LLC
    Redeemable Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $11.50 per share   MDAIW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

      

    On November 18, 2024, Spectral AI, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”) for the sale of up to $5,000,000 in shares of common stock of the Company, par value 0.0001 per share (“Common Stock”). On December 12, 2024, the Investor delivered a purchase notice under the Purchase Agreement for the purchase of 500,000 shares of Common Stock (the “Shares”), at an offering price of $1.80 per share (such transaction, the “Offering”).

     

    The sale and issuance of the Shares is being made pursuant to the Company’s registration statement on Form S-3 (file number 333-282681) (the “Registration Statement”), filed with the Securities and Exchange Commission (the “SEC”) on October 16, 2024 and declared effective on October 31, 2024, and the Company’s prospectus supplement relating to the Offering, which was filed with the SEC on December 12, 2024, that forms part of the Registration Statement.

      

    The Purchase Agreement contains customary representations, warranties and agreements by us and customary conditions to closing. Under the Purchase Agreement, subject to certain exceptions, the Investor has an option (the “Option”) to purchase additional shares of Common Stock (“Additional Shares”) up to the lesser of (i) $5,000,000 in aggregate proceeds or (ii) the remaining available capacity based on one-third of our public float pursuant to General Instruction I.B.6 of Form S-3 (such amount, the “Commitment Amount”). In the event the Option is exercised, the price of any Additional Shares sold shall be the lesser of (x) the closing price of our Common Stock on the previous trading day or (y) the 5-day volume-weighted average price of our Common Stock. We have agreed, under the Purchase Agreement, to grant to the Investor the right of first refusal for any equity offering during the period commencing on the effective date of the Purchase Agreement and expiring on the date that is ten business days following the date on which the Investor has purchased securities equal to the Commitment Amount under the Purchase Agreement, subject to certain exceptions.

      

    A copy of the legal opinion of Reed Smith LLP, relating to the validity of the Shares in connection with the Offering is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any offer, solicitation or sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

     

    The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to such document (or form thereof), which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    1

     

     

    This report contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include statements related to the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering, the intended use of proceeds from the registered direct offering and other statements that are not statements of historical fact and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. Important factors that could cause the Company's actual results to differ materially from those indicated in the forward-looking statements are more fully discussed in the Company's periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described under the heading “Risk Factors” in the Company's annual report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 29, 2024, and other documents subsequently filed with or furnished to the SEC.

     

    Any forward-looking statement made in this Current Report on Form 8-K speaks only as of the date hereof. Factors or events that could cause the Company's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number   Exhibit Description
    5.1   Opinion of Reed Smith LLP.
    10.1   Form of Securities Purchase Agreement, dated November 18, 2024.
    23.1   Consent of Reed Smith LLP (contained in Exhibit 5.1).
    104   Cover Page Interactive Data File (formatted as Inline XBRL).

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: March 4, 2025

     

      SPECTRAL AI, INC.
       
      By: /s/ Vincent S. Capone
      Name:  Vincent S. Capone
      Title:

    Chief Financial Officer and General Counsel

     

     

    3

     

    Get the next $MDAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDAI

    DatePrice TargetRatingAnalyst
    1/23/2024$4.00Buy
    BTIG Research
    More analyst ratings

    $MDAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Spectral AI Names Vincent S. Capone as Chief Executive Officer

    DALLAS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the Company's Board of Directors has appointed Vincent S. Capone as Chief Executive Officer of the Company, effective February 9, 2026. The appointment of Mr. Capone, who currently serves as the Company's Chief Financial Officer and General Counsel, comes as Spectral AI transitions towards commercialization of its proprietary, non-invasive, AI-driven burn wound assessment device – the DeepView® System. "Vince brings a unique set

    2/10/26 8:30:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI to Participate in National Burn Awareness Week 2026 February 1–7, 2026

    DALLAS, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will join the American Burn Association (ABA) to promote practical, life-saving burn prevention strategies for workplaces of all types during this year's National Burn Awareness Week. In support of this annual event, Spectral AI will host a series of internal activities to engage employees, including inspiring messages from leadership, personal stories from biomedical engineers highlighting the importance of innovation in burn

    2/2/26 8:30:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Announces 2025 Third Quarter Financial Results

    Q3 Overview Research & Development Revenue of $3.8 Million; $15.6 Million in YTD Revenue for 2025Strong Cash position of $10.5 Million and progress toward FDA De Novo submission DALLAS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the third quarter ended September 30, 2025 and provided an update on its ongoing business activities. The Company maintained a strong cash position of $10.5 million, recorded $3.8 million in research and development revenue, and continue

    11/11/25 4:00:00 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dimaio John Michael was granted 11,700 shares, increasing direct ownership by 0.47% to 2,503,608 units (SEC Form 4)

    4 - Spectral AI, Inc. (0001833498) (Issuer)

    6/10/25 4:01:14 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Director Mellish Martin C.B. was granted 5,000 shares, increasing direct ownership by 26% to 24,398 units (SEC Form 4)

    4 - Spectral AI, Inc. (0001833498) (Issuer)

    6/6/25 4:00:24 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Director Cotton Richard John was granted 9,699 shares, increasing direct ownership by 17% to 66,927 units (SEC Form 4)

    4 - Spectral AI, Inc. (0001833498) (Issuer)

    5/1/25 4:00:30 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Spectral AI Inc.

    SCHEDULE 13G - Spectral AI, Inc. (0001833498) (Subject)

    2/11/26 2:31:32 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Spectral AI, Inc. (0001833498) (Filer)

    2/10/26 4:01:26 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Spectral AI, Inc. (0001833498) (Filer)

    2/3/26 4:01:39 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Spectral AI with a new price target

    BTIG Research initiated coverage of Spectral AI with a rating of Buy and set a new price target of $4.00

    1/23/24 7:24:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Dimaio John Michael bought $10,320 worth of shares (6,000 units at $1.72), increasing direct ownership by 0.40% to 2,491,908 units (SEC Form 4)

    4 - Spectral AI, Inc. (0001833498) (Issuer)

    5/14/24 11:17:43 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    Financials

    Live finance-specific insights

    View All

    Spectral AI Announces 2025 Third Quarter Financial Results

    Q3 Overview Research & Development Revenue of $3.8 Million; $15.6 Million in YTD Revenue for 2025Strong Cash position of $10.5 Million and progress toward FDA De Novo submission DALLAS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the third quarter ended September 30, 2025 and provided an update on its ongoing business activities. The Company maintained a strong cash position of $10.5 million, recorded $3.8 million in research and development revenue, and continue

    11/11/25 4:00:00 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Schedules 2025 Third Quarter Financial Results and Conference Call

    DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the third quarter ended September 30, 2025 on Tuesday, November 11, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results. Investors interested in participating in the live call can dial: 833-630-1956 – U.S.412-317-1837 – International A simultaneous webcast of the call may be accessed online fr

    10/28/25 4:00:00 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Announces 2025 Second Quarter Financial Results

    Q2 Overview Research & Development Revenue of $5.1 Million, total revenue for the first half of 2025 of $11.8 MillionStrong Cash position of $10.5 MillionSubmission of De Novo application to FDA completed in Second Quarter of 2025 DALLAS, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the second quarter ended June 30, 2025 and provided an update on its ongoing business activities. "We are pleased with the results of our second quarter of 2025 especially with our ab

    8/12/25 4:00:00 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    Leadership Updates

    Live Leadership Updates

    View All

    Spectral AI Names Vincent S. Capone as Chief Executive Officer

    DALLAS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the Company's Board of Directors has appointed Vincent S. Capone as Chief Executive Officer of the Company, effective February 9, 2026. The appointment of Mr. Capone, who currently serves as the Company's Chief Financial Officer and General Counsel, comes as Spectral AI transitions towards commercialization of its proprietary, non-invasive, AI-driven burn wound assessment device – the DeepView® System. "Vince brings a unique set

    2/10/26 8:30:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer

    DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company's Chief Operating Officer ("COO"). Micek's promotion reflects his role change from Interim COO of the Company since May, 2024 "Stan has demonstrated exceptional leadership, operational insight, and a deep understanding of our business during his time as interim COO," said Dr. J. Michael DiMaio, M.D., Chairman of the Company's Board of Directors. "His efforts leading our Research and Devel

    5/30/25 8:00:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Announces Voting Results from 2025 Annual Meeting of Stockholders

    DALLAS, May 29, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced results from its 2025 Annual Meeting of Stockholders held earlier today. A total of 15,551,068 shares representing 60.8% of the Company's total shares outstanding were represented at the meeting, either in person or by proxy. Both of the proposals set forth by the Company were approved by its stockholders. The voting results are detailed below. Six directors were elected to serve on the Company's Board of Directors until the next Annual Me

    5/29/25 8:00:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Spectral AI Inc.

    SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)

    11/14/24 4:09:49 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Spectral AI Inc. (Amendment)

    SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)

    4/19/24 6:49:51 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Spectral AI Inc. (Amendment)

    SC 13D/A - Spectral AI, Inc. (0001833498) (Subject)

    2/27/24 2:07:28 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care